Anthracycline-induced cardiotoxicity and senescence

Area of Science:

• Cardiology
• Oncology
• Cellular Biology

Background:

• Cancer survivorship is improving, but cardiotoxicity from cancer therapies is a growing concern, leading to heart failure in survivors.
• Chemotherapy-induced cardiotoxicity is a significant clinical issue, with cellular senescence emerging as a key underlying mechanism.
• Cellular senescence, characterized by cell cycle arrest and a pro-inflammatory phenotype, is implicated in aging-related cardiovascular disease.

Purpose of the Study:

• To review the evidence linking anthracycline-induced cellular senescence to long-term cardiotoxicity from cancer chemotherapies.
• To explore how the senescent phenotype contributes to myocardial dysfunction.
• To examine the therapeutic potential of targeting cellular senescence to prevent or reverse chemotherapy-induced cardiac dysfunction.

Main Methods:

• Review of existing literature on chemotherapy-induced cardiotoxicity and cellular senescence.
• Analysis of studies investigating the mechanisms of senescence-associated myocardial remodeling.
• Examination of preclinical data on senolytics in models of cardiotoxicity.

Main Results:

• Cellular senescence is a recognized response to chemotherapies like anthracyclines, involving cell cycle exit and altered cellular functions.
• Senescence contributes to myocardial remodeling and cardiovascular disease, and its elimination can attenuate cardiac pathology.
• Senolytics have shown efficacy in preventing myocardial dysfunction in preclinical models of chemotherapy-induced cardiotoxicity.

Conclusions:

• Anthracycline-induced senescence is a likely cause of long-term cardiotoxicity from cancer treatments.
• Targeting cellular senescence represents a promising therapeutic strategy for preventing and potentially reversing chemotherapy-induced cardiac dysfunction.
• Senolytics offer a novel approach to mitigate the cardiovascular side effects of cancer therapy, improving long-term outcomes for survivors.